Quick Answer
Royalty Pharma plc reported Operating Income Loss of $1.56 billion for the year ending 2025.
- Royalty Pharma plc showed an increase of +20.7% in Operating Income Loss from 2024 to 2025.
- This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Royalty Pharma plc's Operating Income Loss has grown by 14.3%.
- Historical annual values: Fiscal year 2025: $1.56 billion | Fiscal year 2024: $1.29 billion | Fiscal year 2023: $1.49 billion | Fiscal year 2022: $307.07 million | Fiscal year 2021: $1.43 billion | Fiscal year 2020: $1.60 billion | Fiscal year 2019: $2.62 billion | Fiscal year 2018: $1.36 billion.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: